Biohaven BHVN Total debt

Total debt at other companies

Eli LillyLLY

$54.91B+37.6%

Xenon PharmaceuticalsXENE

$6.42M-26.4%

Rapport Therapeutics, Inc.RAPP

$10.11M-14.8%

Vir Biotechnology, Inc.VIR

$93.27M-8.8%

Monte Rosa Therapeutics, Inc.GLUE

$37.99M-7.6%

Avalo TherapeuticsAVTX

$242K-64.4%

FAQ

What is Biohaven's total debt?

Biohaven (BHVN) reported total debt of $286.18M in Q1 2026.

How has Biohaven's total debt changed year-over-year?

Biohaven's total debt increased by 705.9% year-over-year, from $35.51M to $286.18M.

What is the long-term trend for Biohaven's total debt?

Over 4 years (2021 to 2025), Biohaven's total debt has grown at a 206.2% compound annual growth rate (CAGR), from $3.24M to $284.61M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.